Zhang Y, Rumgay H, Li M, Yu H, Pan H, Ni J (2023) The global landscape of bladder cancer incidence and mortality in 2020 and projections to 2040. J Glob Health 13:04109. https://doi.org/10.7189/jogh.13.04109

Article  PubMed  PubMed Central  Google Scholar 

EAU Guidelines. Edn. presented at the EAU Annual Congress Paris 2024. ISBN 978-94-92671-23-3. EAU Guidelines Office, Arnhem, The Netherlands. https://uroweb.org/guidelines

Powles T, Bellmunt J, Comperat E, De Santis M, Huddart R, Loriot Y, Necchi A, Valderrama BP, Ravaud A, Shariat SF, Szabados B, van der Heijden MS, Gillessen S, ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org (2024) ESMO clinical practice guideline interim update on first-line therapy in advanced urothelial carcinoma. Ann Oncol 35(6):485–490. https://doi.org/10.1016/j.annonc.2024.03.001

Flaig TW, Spiess PE, Abern M, Agarwal N, Bangs R, Buyyounouski MK, Chan K, Chang SS, Chang P, Friedlander T, Greenberg RE, Guru KA, Herr HW, Hoffman-Censits J, Kaimakliotis H, Kishan AU, Kundu S, Lele SM, Mamtani R, Mian OY, Michalski J, Montgomery JS, Parikh M, Patterson A, Peyton C, Plimack ER, Preston MA, Richards K, Sexton WJ, Siefker-Radtke AO, Stewart T, Sundi D, Tollefson M, Tward J, Wright JL, Cassara CJ, Gurski LA (2024) NCCN Guidelines® insights: bladder cancer, version 3.2024. J Natl Compr Canc Netw 22(4):216–225. https://doi.org/10.6004/jnccn.2024.0024

Article  CAS  PubMed  Google Scholar 

Witjes JA, Bruins HM, Cathomas R et al (2021) EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Assoc Urol 79(1):82–104. https://doi.org/10.1016/j.eururo.2020.03.055

Article  CAS  Google Scholar 

Powles T, Rosenberg JE, Sonpavde GP, Loriot Y, Durán I, Lee JL, Matsubara N, Vulsteke C, Castellano D, Wu C, Campbell M, Matsangou M, Petrylak DP (2021) Enfortumab Vedotin in previously treated advanced urothelial carcinoma. N Engl J Med 384(12):1125–1135. https://doi.org/10.1056/NEJMoa2035807

Article  CAS  PubMed  PubMed Central  Google Scholar 

Srinivasalu VK, Robbrecht D (2024) Advancements in First-Line treatment of metastatic bladder cancer: EV-302 and Checkmate-901 insights and future directions. Cancers (Basel) 16:2398. https://doi.org/10.3390/cancers16132398

Article  CAS  PubMed  Google Scholar 

Powles TB, Perez Valderrama B, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, Iyer G, Vulsteke C, Park SH, Shin SJ, Castellano Gauna DE, Fornarini G, Li JR, Gumus M, Mar N, Narayanan S, Yu X, Gorla S, Homet Moreno, van der Heijden BMS (2023) [LBA6] EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV1P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC). Ann Oncol 34:S1340. https://doi.org/10.1016/j.annonc.2023.10.106

Klümper N, Ralser DJ, Ellinger J, Roghmann F, Albrecht J, Below E, Alajati A, Sikic D, Breyer J, Bolenz C, Zengerling F, Erben P, Schwamborn K, Wirtz RM, Horn T, Nagy D, Toma M, Kristiansen G, Büttner T, Hahn O, Grünwald V, Darr C, Erne E, Rausch S, Bedke J, Schlack K, Abbas M, Zschäbitz S, Schwab C, Mustea A, Adam P, Manseck A, Wullich B, Ritter M, Hartmann A, Gschwend J, Weichert W, Erlmeier F, Hölzel M, Eckstein M (2023) Membranous NECTIN-4 expression frequently decreases during metastatic spread of urothelial carcinoma and is associated with enfortumab Vedotin resistance. Clin Cancer Res 29(8):1496–1505. https://doi.org/10.1158/1078-0432.CCR-22-1764

Article  PubMed  Google Scholar 

Klümper N, Tran NK, Zschäbitz S, Hahn O, Büttner T, Roghmann F, Bolenz C, Zengerling F, Schwab C, Nagy D, Toma M, Kristiansen G, Heers H, Ivanyi P, Niegisch G, Grunewald CM, Darr C, Farid A, Schlack K, Abbas M, Aydogdu C, Casuscelli J, Mokry T, Mayr M, Niedersüß-Beke D, Rausch S, Dietrich D, Saal J, Ellinger J, Ritter M, Alajati A, Kuppe C, Meeks J, Vera Badillo FE, Nakauma-González JA, Boormans J, Junker K, Hartmann A, Grünwald V, Hölzel M, Eckstein M (2024) NECTIN4 amplification is frequent in solid tumors and predicts enfortumab Vedotin response in metastatic urothelial Cancer. J Clin Oncol 42(20):2446–2455. https://doi.org/10.1200/JCO.23.01983

Article  CAS  PubMed  Google Scholar 

Miyake M, Oda Y, Nishimura N, Shimizu T, Fujii T, Fujimoto K (2023) Chemotherapy with gemcitabine and cisplatin downregulates tumor expression level of nectin-4 in a syngeneic model of murine MBT2 urothelial cancer cell line and C3H mice. Int J Urol 30(3):328–330. https://doi.org/10.1111/iju.15109

Article  CAS  PubMed  Google Scholar 

Miyake M, Miyamoto T, Shimizu T, Ohnishi S, Fujii T, Nishimura N, Oda Y, Morizawa Y, Hori S, Gotoh D, Nakai Y, Torimoto K, Tanaka N, Fujimoto K (2022) Tumor expression of Nectin-1-4 and its clinical implication in muscle invasive bladder cancer: an intra-patient variability of Nectin-4 expression. Pathol Res Pract 237:154072. https://doi.org/10.1016/j.prp.2022.154072

Article  CAS  PubMed  Google Scholar 

Seiler R, Gibb EA, Wang NQ, Oo HZ, Lam HM, van Kessel KE, Voskuilen CS, Winters B, Erho N, Takhar MM, Douglas J, Vakar-Lopez F, Crabb SJ, van Rhijn BWG, van de Fransen EE, Zwarthoff EC, Thalmann GN, Davicioni E, Boormans JL, Dall’Era M, van der Heijden MS, Wright JL, Black PC (2019) Divergent biological response to neoadjuvant chemotherapy in Muscle-invasive bladder Cancer. Clin Cancer Res 25(16):5082–5093. https://doi.org/10.1158/1078-0432.CCR-18-1106

Article  CAS  PubMed  Google Scholar 

Chu CE, Sjöström M, Egusa EA, Gibb EA, Badura ML, Zhu J, Koshkin VS, Stohr BA, Meng MV, Pruthi RS, Friedlander TW, Lotan Y, Black PC, Porten SP, Feng FY, Chou J (2021) Heterogeneity in NECTIN4 expression across molecular subtypes of urothelial Cancer mediates sensitivity to enfortumab Vedotin. Clin Cancer Res 27(18):5123–5130. https://doi.org/10.1158/1078-0432.CCR-20-4175

Article  CAS  PubMed  PubMed Central  Google Scholar 

Drago JZ, Modi S, Chandarlapaty S (2021) Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat Rev Clin Oncol 18(6):327–344. https://doi.org/10.1038/s41571-021-00470-8

Article  PubMed  PubMed Central  Google Scholar 

Khoury R, Saleh K, Khalife N, Saleh M, Chahine C, Ibrahim R, Lecesne A (2023) Mechanisms of resistance to Antibody-Drug conjugates. Int J Mol Sci 4(11):9674. https://doi.org/10.3390/ijms24119674

Article  CAS  Google Scholar 

Miura N, Takemori N, Kikugawa T, Tanji N, Higashiyama S, Yokoyama M (2012) Adseverin: a novel cisplatin-resistant marker in the human bladder cancer cell line HT1376 identified by quantitative proteomic analysis. Mol Oncol 6(3):311–322. https://doi.org/10.1016/j.molonc.2011.12.002

Article  CAS  PubMed  PubMed Central  Google Scholar 

Okamura S, Yoshino H, Kuroshima K, Tsuruda M, Osako Y, Sakaguchi T, Yonemori M, Yamada Y, Tatarano S, Nakagawa M, Enokida H (2021) EHHADH contributes to cisplatin resistance through regulation by tumor-suppressive MicroRNAs in bladder cancer. BMC Cancer 21(1):48. https://doi.org/10.1186/s12885-020-07717-0

Article  CAS  PubMed  PubMed Central  Google Scholar 

Miyake M, Hori S, Itami Y, Oda Y, Owari T, Fujii T, Ohnishi S, Morizawa Y, Gotoh D, Nakai Y, Anai S, Torimoto K, Tanaka N, Fujimoto K (2020) Supplementary oral Anamorelin mitigates anorexia and skeletal muscle atrophy induced by gemcitabine plus cisplatin systemic chemotherapy in a mouse model. Cancers (Basel) 12(7):1942. https://doi.org/10.3390/cancers12071942

Article  CAS  PubMed  Google Scholar 

Miyake M, Ishii M, Koyama N, Kawashima K, Kodama T, Anai S, Fujimoto K, Hirao Y, Sugano K (2010) 1-tert-butyl-3-[6-(3,5-dimethoxy-phenyl)-2-(4-diethylamino-butylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea (PD173074), a selective tyrosine kinase inhibitor of fibroblast growth factor receptor-3 (FGFR3), inhibits cell proliferation of bladder cancer carrying the FGFR3 gene mutation along with up-regulation of p27/Kip1 and G1/G0 arrest. J Pharmacol Exp Ther 332(3):795–802. https://doi.org/10.1124/jpet.109.162768

Article  CAS  PubMed  Google Scholar 

Miyake M, Anai S, Fujimoto K, Ohnishi S, Kuwada M, Nakai Y, Inoue T, Tomioka A, Tanaka N, Hirao Y (2012) 5-fluorouracil enhances the antitumor effect of Sorafenib and Sunitinib in a xenograft model of human renal cell carcinoma. Oncol Lett 3(6):1195–1202. https://doi.org/10.3892/ol.2012.662

Article  CAS  PubMed  PubMed Central  Google Scholar 

Miyake M, Hori S, Morizawa Y, Tatsumi Y, Toritsuka M, Ohnishi S, Shimada K, Furuya H, Khadka VS, Deng Y, Ohnishi K, Iida K, Gotoh D, Nakai Y, Inoue T, Anai S, Torimoto K, Aoki K, Tanaka N, Konishi N, Fujimoto K (2017) Collagen type IV alpha 1 (COL4A1) and collagen type XIII alpha 1 (COL13A1) produced in cancer cells promote tumor budding at the invasion front in human urothelial carcinoma of the bladder. Oncotarget 8(22):36099–36114. https://doi.org/10.18632/oncotarget.16432

Article  PubMed  PubMed Central  Google Scholar 

The Gene Ontology Consortium (2019) The gene ontology resource: 20 years and still going strong. Nucleic Acids Res 47(D1):D330–D338. https://doi.org/10.1093/nar/gky1055

Kanehisa M, Araki M, Goto S, Hattori M, Hirakawa M, Itoh M, Katayama T, Kawashima S, Okuda S, Tokimatsu T, Yamanishi Y (2008) KEGG for linking genomes to life and the environment. Nucleic Acids Res 36(Database issue):D480–D484. https://doi.org/10.1093/nar/gkm882

Article  CAS  PubMed  Google Scholar 

Lopez-Beltran A, Blanca A, Cimadamore A, Gogna R, Montironi R, Cheng L (2021) Molecular classification of bladder urothelial carcinoma using NanoString-Based gene expression analysis. Cancers (Basel) 13(21):5500. https://doi.org/10.3390/cancers13215500

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mokkapati S, Manyam G, Steinmetz AR, Tholomier C, Martini A, Choi W, Czerniak B, Lee BH, Dinney CP, McConkey DJ (2025) Molecular profiling of bladder cancer xenografts defines relevant molecular subtypes and provides a resource for biomarker discovery. Transl Oncol 52:102269. https://doi.org/10.1016/j.tranon.2024.102269

Article  CAS  PubMed  PubMed Central  Google Scholar 

Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, Hinoue T, Laird PW, Hoadley KA, Akbani R, Castro MAA, Gibb EA,